
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences is a synthetic lethality-focused precision medicine oncology company with a strong cash position and multiple clinical and preclinical programs. Recently completed offerings and collaborations, combined with positive early data for darovasertib combination therapies, provide potential validation and competitive advantages against other companies in the market. However, there are risks to the attainment of its price target, including clinical and regulatory failure, as well as potential commercial challenges from competing therapies. Despite these risks, the company's strong cash position and promising combination therapies make it an attractive investment opportunity.
Bears say
IDEAYA Biosciences is facing several challenges as an oncology-focused precision medicine company, including the potential for regulatory execution setbacks and competition from similar companies with new technologies. Additionally, there is a high risk that sales from their clinical-stage product candidates, particularly darovasertib and IDE397, may not meet expectations due to the high unmet need in the market. These risks, along with potential dilutive financing, may negatively impact the company's financials in the future.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares